Drug-eluting Balloon Catheters Market Analysis

Drug-eluting Balloon Catheters Market Analysis

To get key market trends

  Download Free Sample

The market by product is categorized into coronary artery disease DEB catheters, and peripheral vascular disease DEB catheters. The peripheral vascular disease DEB catheters segment held leading revenue share and was valued at over USD 323 million in 2022.
 

• DEB catheters, with their drug-coated technology, have the ability to minimize the risk of restenosis, is a significant factor driving the adoption of DEB catheters for peripheral vascular disease interventions.
   
• Research and clinical experience supporting the use of DEB catheters in a broader range of peripheral vessels including treatment of various types of peripheral arterial lesions.
   
• Peripheral vascular disease DEB catheters, often used in minimally invasive procedures, align well with the trend toward outpatient interventions, leading to increased demand for wide range of procedures.
   

Based on material, the drug-eluting balloon catheters market is segmented into polyurethane, nylon, and other materials. The polyurethane segment accounted for significant share in 2022 and was valued at over USD 204 million.
 

• Polyurethane offers good flexibility, allowing the catheter to navigate through tortuous vessels. Improved flexibility enhances the maneuverability of drug-eluting balloon catheters, making them suitable for a variety of vascular anatomies.
   
• Some polyurethane formulations can be made radiopaque as radiopacity is crucial for visualization during procedures, allowing healthcare professionals to monitor the catheter's position using fluoroscopy or other medical imaging techniques
   
• Positive clinical outcomes with polyurethane-based drug-eluting balloon catheters in clinical studies and real-world scenarios.

The drug-eluting balloon catheters market by end-use is categorized into hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. The hospitals and clinics segment is projected to reach over USD 964 million revenue size in 2032.
 

• Drug-eluting balloon catheters offer a minimally invasive alternative to traditional interventions, such as open-heart surgery or bypass procedures. Patients often prefer less invasive options, and healthcare providers are increasingly adopting these catheters for procedures in hospitals and clinics.
   
• Drug-eluting balloon catheters, by delivering therapeutic agents to the treated site, aim to reduce the risk of restenosis (re-narrowing of the blood vessel). The potential for improved long-term outcomes makes these catheters appealing for use in these healthcare settings.
   
• Favorable reimbursement policies for procedures involving drug-eluting balloon catheters encourages healthcare providers to offer these interventions in hospitals and clinics.

North America drug-eluting balloon catheters market accounted for USD 254.9 million revenue in 2022.
 

• The aging population is more prone to cardiovascular diseases and as the population ages, there is a corresponding increase in the demand for interventions, including drug-eluting balloon catheters, to address cardiovascular conditions. For instance, there are more than 350,000 Coronary artery bypass graft surgery (CABG) surgeries performed each year in the U.S.
   
• Drug-eluting balloon catheters are used for the treatment of complex lesions, including in-stent restenosis. The effectiveness in addressing challenging cases contributes to the adoption of these catheters in regional healthcare settings.
   
• Growing awareness among healthcare professionals and patients about advanced interventional options coupled with increased understanding of the benefits of drug-eluting balloon catheters.